Paper22871663
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E and 16 others. Mol Ther, 2012. Cited by 132 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Papers, record 22871663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22871663
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mammalian orthoreovirus 3 | Major topic |
| Melanoma | Major topic |
| Oncolytic Virotherapy | Major topic |
| Administration, Intravenous | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Proto-Oncogene Proteins | |
| Proto-Oncogene Proteins B-raf | |
| Proto-Oncogene Proteins p21(ras) | |
| Virus Replication | |
| Young Adult | |
| ras Proteins |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| N01CM 62205-5 | NCI NIH HHS | United States | N01CM622055 | PubMed | NIH RePORTER |
| N01 CM062205 | NCI NIH HHS | United States | N01CM062205 | PubMed | NIH RePORTER |
| R01 CA107082 | NCI NIH HHS | United States | R01CA107082 | PubMed and NIH | NIH RePORTER |
| R01 CA154348 | NCI NIH HHS | United States | R01CA154348 | PubMed and NIH | NIH RePORTER |
| R01 CA130878 | NCI NIH HHS | United States | R01CA130878 | PubMed and NIH | NIH RePORTER |
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20,587,792 | Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20587792 | PubMed |
| 2 | 18,401,435 | Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. | Gene Ther | 2008 | https://conductscience.org/library/papers/18401435 | PubMed |
| 3 | 18,981,012 | A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18981012 | PubMed |
| 4 | 19,572,105 | Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19572105 | PubMed |
| 5 | 11,007,773 | Transcriptional activities of reovirus RNA polymerase in recoated cores. Initiation and elongation are regulated by separate mechanisms. | J Biol Chem | 2000 | https://conductscience.org/library/papers/11007773 | PubMed |
| 6 | 9,628,872 | The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. | EMBO J | 1998 | https://conductscience.org/library/papers/9628872 | PubMed |
| 7 | 2,982,027 | Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. | J Virol | 1985 | https://conductscience.org/library/papers/2982027 | PubMed |
| 8 | 4,371,523 | The reovirus murine models. | Prog Med Virol | 1974 | https://conductscience.org/library/papers/4371523 | PubMed |
| 9 | 19,773,377 | Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19773377 | PubMed |
| 10 | 19,594,950 | Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. | Mol Cancer | 2009 | https://conductscience.org/library/papers/19594950 | PubMed |
| 11 | 19,884,534 | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19884534 | PubMed |
| 12 | 18,172,278 | Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18172278 | PubMed |
| 13 | 21,886,163 | Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. | Nature | 2011 | https://conductscience.org/library/papers/21886163 | PubMed |
| 14 | 21,107,323 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | Nature | 2010 | https://conductscience.org/library/papers/21107323 | PubMed |
| 15 | 20,801,221 | The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. | Methods | 2010 | https://conductscience.org/library/papers/20801221 | PubMed |
| 16 | 21,106,728 | A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21106728 | PubMed |
| 17 | 19,509,134 | Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19509134 | PubMed |
| 18 | 11,932,414 | Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. | J Virol | 2002 | https://conductscience.org/library/papers/11932414 | PubMed |
| 19 | 21,639,808 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21639808 | PubMed |
| 20 | 20,528,232 | OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. | Future Oncol | 2010 | https://conductscience.org/library/papers/20528232 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,817,273 | Enhanced sialic acid engagement at physiological temperatures by reovirus σ1 mutants facilitates infection of breast cancer cells with low levels of high-affinity receptors. | J Virol | 2026 | https://conductscience.org/library/papers/41817273 | PubMed |
| 41,792,783 | Reovirus resistance in tumors mediated by elevated ISG expression: overcoming therapeutic resistance via JAK/STAT pathway modulation. | Virol J | 2026 | https://conductscience.org/library/papers/41792783 | PubMed |
| 41,696,944 | Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41696944 | PubMed |
| 41,315,764 | Innate immunity in tumour immunoediting and immunosurveillance. | EMBO J | 2026 | https://conductscience.org/library/papers/41315764 | PubMed |
| 41,150,456 | Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/41150456 | PubMed |
| 40,991,899 | A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses. | Cancer Control | 2025 | https://conductscience.org/library/papers/40991899 | PubMed |
| 40,734,810 | Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer. | Gastroenterol Hepatol Bed Bench | 2025 | https://conductscience.org/library/papers/40734810 | PubMed |
| 40,539,780 | Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis. | J Virol | 2025 | https://conductscience.org/library/papers/40539780 | PubMed |
| 40,480,657 | Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40480657 | PubMed |
| 40,365,251 | Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here? | Skin Health Dis | 2025 | https://conductscience.org/library/papers/40365251 | PubMed |
| 39,772,250 | Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection. | Viruses | 2024 | https://conductscience.org/library/papers/39772250 | PubMed |
| 39,013,849 | Exploring treatment options in cancer: Tumor treatment strategies. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39013849 | PubMed |
| 38,771,042 | Sequence polymorphisms in the reovirus σ1 attachment protein modulate encapsidation efficiency and replication in mice. | J Virol | 2024 | https://conductscience.org/library/papers/38771042 | PubMed |
| 38,194,598 | Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. | Cancer Immunol Res | 2024 | https://conductscience.org/library/papers/38194598 | PubMed |
| 38,033,400 | Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/38033400 | PubMed |
| 37,919,738 | The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis. | Virol J | 2023 | https://conductscience.org/library/papers/37919738 | PubMed |
| 37,686,579 | Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686579 | PubMed |
| 37,629,523 | New Treatment Horizons in Uveal and Cutaneous Melanoma. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37629523 | PubMed |
| 37,515,162 | Modulation of Reoviral Cytolysis (II): Cellular Stemness. | Viruses | 2023 | https://conductscience.org/library/papers/37515162 | PubMed |
| 37,458,862 | Oncolytic viruses against cancer, promising or delusion? | Med Oncol | 2023 | https://conductscience.org/library/papers/37458862 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| KRAS | 3,845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22871663
GET https://conductscience.org/api/papers/v1/22871663/references?page=2